EU to Rule on Safety of Novartis’s Gilenya MS Pill

April 18, 2012
Europe’s drug regulator will likely allow Novartis’ Gilenya to stay on the market without asking for much stricter safety warnings as it concludes a review of the multiple sclerosis pill initiated after reports of heart problems and the death of a patient who took the drug.